Saltar al contenido
MilliporeSigma
Todas las fotos(2)

Documentos clave

Ver Toda la documentación

L3791

Sigma-Aldrich

Lamotrigine

≥98% (TLC), powder, glutamate release inhibitor

Sinónimos:

6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine, GI 267119X

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

10 MG
$153.90
50 MG
$612.48

$153.90

Precio de catálogo$171.00Ahorre 10 %

En stockDetalles

Solicitar un pedido a granel
Todas las fotos(2)

Seleccione un Tamaño

Cambiar Vistas
10 MG
$153.90
50 MG
$612.48

About This Item

Fórmula empírica (notación de Hill):
C9H7Cl2N5
Número de CAS:
84057-84-1
Peso molecular:
256.09
EC Number:
281-901-8
MDL number:
MFCD00865333
UNSPSC Code:
12352200
PubChem Substance ID:
24278792
NACRES:
NA.77

$153.90

Precio de catálogo$171.00Ahorre 10 %

En stockDetalles

Solicitar un pedido a granel

Nombre del producto

Lamotrigine, ≥98%, powder

Quality Level

200

assay

≥98%

form

powder

color

white

solubility

DMSO: soluble 20 mg/mL at 60 °C
H2O: insoluble

originator

GlaxoSmithKline

storage temp.

2-8°C

SMILES string

Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl

InChI

1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

InChI key

PYZRQGJRPPTADH-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
rat ... Scn2a1(24766) , Scnn1a(25122)

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

Anticonvulsant.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
MKCW2040
MKCH9792
MKCF2209
MKCB1463V
MKBV1400V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Chaitali Ghosh et al.
Epilepsia, 54(9), 1562-1570 (2013-07-20)
Brain drug bioavailability is regulated by the blood-brain barrier (BBB). It was recently suggested that cytochrome P450 (CYP) enzymes could act in concert with multidrug transporter proteins to regulate drug penetration and distribution into the diseased brain. The possibility that
Stacey Shim et al.
The Journal of pharmacology and experimental therapeutics, 347(2), 487-496 (2013-08-30)
Carisbamate and lamotrigine are anticonvulsants that act on neuronal voltage-gated sodium channels. Carisbamate has shown antidepressant-like effects in animal models of depression, and lamotrigine is a mood stabilizer with a therapeutic effect in depressive episodes of patients with bipolar disorder.
Allyson K Friedman et al.
Science (New York, N.Y.), 344(6181), 313-319 (2014-04-20)
Typical therapies try to reverse pathogenic mechanisms. Here, we describe treatment effects achieved by enhancing depression-causing mechanisms in ventral tegmental area (VTA) dopamine (DA) neurons. In a social defeat stress model of depression, depressed (susceptible) mice display hyperactivity of VTA
Kerstin Römermann et al.
Neuropharmacology, 93, 7-14 (2015-02-04)
Resistance to antiepileptic drugs (AEDs) is the major problem in the treatment of epilepsy. One hypothesis to explain AED resistance suggests that seizure-induced overexpression of efflux transporters at the blood-brain barrier (BBB) restricts AEDs to reach their brain targets. Various
Jennifer G Reid et al.
The Journal of clinical psychiatry, 74(7), 675-684 (2013-08-16)
Owing to the prevalence of medication side effects and treatment resistance, prescribers often consider off-label uses of US Food and Drug Administration (FDA)-approved agents for the treatment of persistent symptoms. The authors review the available literature on the FDA-approved and
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico